Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

ORGS - Orgenesis Inc Stock Price, Fair Value and News

$0.90-0.10 (-10.00%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

ORGS Price Action

Last 7 days

12.5%

Last 30 days

-13.5%

Last 90 days

-55.2%

Trailing 12 Months

-88.9%

ORGS Stock Price

ORGS RSI Chart

NovDec2025FebMarAprMayJunJulAug0102030405060708090

ORGS Valuation

Market Cap

5.2M

Price/Earnings (Trailing)

-0.09

Price/Sales (Trailing)

5.75

EV/EBITDA

-0.32

Price/Free Cashflow

-0.33

ORGS Price/Sales (Trailing)

2023202420250102030405060

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ORGS Fundamentals

ORGS Revenue

Revenue (TTM)

899.0K

2012201420162018202020222024010M20M30M40M

ORGS Earnings

Earnings (TTM)

-55.4M

201220142016201820202022-60M-40M-20M020M40M60M80M

ORGS Profitability

Operating Margin

-97.66%

EBT Margin

-3931.92%

Return on Equity

-446.57%

Return on Assets

-186.48%

Free Cashflow Yield

-304.55%

ORGS Investor Care

Shares Dilution (1Y)

62.16%

Revenue Breakdown

As of: Sep 30, 2024
2020202120222023202402M4M6M8M
Cell Process Development Services And Hospital Services
ProductValuePercent
BusinessValuePercent
GeographyValuePercent
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
201220142016201820202022202405M10M15M20M25M30M35M40M
Net sales
YearQ1Q2Q3Q4
2024529.0K662.0K899.0K0
202327.2M18.3M9.4M530.0K
202235.6M35.8M35.9M36.0M
202131.5M32.8M34.2M35.5M
202032.5M31.7M30.9M30.1M
201923.5M26.0M28.4M33.3M
201813.5M15.2M16.9M18.7M
20177.9M8.6M9.4M10.1M
20163.7M4.3M5.0M6.4M
201501.8M2.4M3.0M
201100596.8K1.2M
20100002.5K
Get all data in R, Python etc through our Historical Stock Data APIs

About Orgenesis Inc

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
 CEO
 WEBSITEorgenesis.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES167

Orgenesis Inc Frequently Asked Questions

What is the ticker symbol for Orgenesis Inc? What does ORGS stand for in stocks?

ORGS is the stock ticker symbol of Orgenesis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Orgenesis Inc (ORGS)?

As of Mon Aug 18 2025, market cap of Orgenesis Inc is 5.17 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORGS stock?

You can check ORGS's fair value in chart for subscribers.

Is Orgenesis Inc a good stock to buy?

The fair value guage provides a quick view whether ORGS is over valued or under valued. Whether Orgenesis Inc is cheap or expensive depends on the assumptions which impact Orgenesis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORGS.

What is Orgenesis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Aug 18 2025, ORGS's PE ratio (Price to Earnings) is -0.09 and Price to Sales (PS) ratio is 5.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORGS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Orgenesis Inc's stock?

In the past 10 years, Orgenesis Inc has provided -0.342 (multiply by 100 for percentage) rate of return.